epirubicin has been researched along with Pyrexia in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, W; Chen, J; Deng, R; Tao, K; Wu, X; Zhang, P | 1 |
| Keller, U; Licht, T; Menzel, H; Müller, A; Peschel, C; Von Schilling, C | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G | 1 |
| Al Zaman, A; Fraser, J; Steele, N; Yule, A | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R | 1 |
| Blackwood, L; Grant, IA; Killick, DR; Marrington, AM | 1 |
| Rayson, D; Thompson, K; Younis, T | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Antimi, M; Barone, C; Botti, C; Calabresi, F; Carlini, P; Conti, F; Cortesi, E; Di Cosimo, S; Di Filippo, F; Di Lauro, L; Fabi, A; Ferretti, G; Giannarelli, D; Lopez, M; Marolla, P; Nisticò, C; Papaldo, P; Terzoli, E; Vici, P | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Ferretti, G; Papaldo, P | 1 |
| Antimi, M; Cognetti, F; Cortesi, E; Ferretti, G; Giannarelli, D; Lopez, M; Marolla, P; Papaldo, P; Terzoli, E | 1 |
| Chen, Y; Liu, QX; Luo, JJ; Wang, JH; Yan, ZP | 1 |
| Li, T; Li, ZW; Wen, HC | 1 |
| Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Dranitsaris, G; Tran, TM | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Bishop, JF; Fenessy, A; Michael, M; Olver, IN; Toner, GC | 1 |
| Arisawa, J; Hosoki, T; Inoue, Y; Masuzawa, M; Monden, M; Monden, T; Nakamura, H; Nakao, N; Ohi, H; Ohsaki, Y; Sakon, M; Seki, K; Shimizu, T; Todo, A; Tomono, N; Yayoi, E | 1 |
| Bell, D; Keefe, DM; Ma, DD; Turtle, CJ; Wheeler, H | 1 |
| de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH | 1 |
| Cottu, PH; Cuvier, C; de Roquancourt, A; Espie, M; Extra, JM; Laurence, V; Lerebours, F; Makke, J; Marolleau, JP; Marty, M; Mayeur, D; Miclea, JM | 1 |
| Boyd, MA; Case, DC; Ervin, TJ; Gams, R; Oldham, FB | 1 |
2 review(s) available for epirubicin and Pyrexia
| Article | Year |
|---|---|
Primary splenic angiosarcoma with fever and anemia: a case report and literature review.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; Epirubicin; Fever; Hemangiosarcoma; Humans; Ifosfamide; Immunohistochemistry; Laparoscopy; Male; Middle Aged; Splenectomy; Splenic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Epirubicin; Fever; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Taxoids | 2012 |
14 trial(s) available for epirubicin and Pyrexia
| Article | Year |
|---|---|
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Time Factors; Young Adult | 2011 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2003 |
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Neutropenia; Recombinant Proteins | 2005 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fever; Fluorouracil; Humans; Iodized Oil; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Survival Rate; Thymopentin | 2007 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Ethinyl Estradiol; Female; Fever; Fluorouracil; Hematologic Diseases; Humans; Infections; Length of Stay; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction | 1993 |
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prospective Studies | 1997 |
[Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubicin; Fever; Hepatic Artery; Humans; Injections, Intra-Arterial; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1998 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxacin; Costs and Cost Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fever; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Length of Stay; Leukopenia; Methotrexate; Middle Aged; Neoplasm Metastasis; Netherlands; Prospective Studies; Recombinant Proteins | 1999 |
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
11 other study(ies) available for epirubicin and Pyrexia
| Article | Year |
|---|---|
Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fever; Humans; Maximum Tolerated Dose; Medical Audit; Middle Aged; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fever; Fluorouracil; Genetic Association Studies; Humans; Middle Aged; Mutation, Missense; Neutropenia; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Sequence Analysis, DNA; Tumor Suppressor Protein p53 | 2012 |
Toxicity associated with epirubicin treatments in a large case series of dogs.
Topics: Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Epirubicin; Female; Fever; Gastrointestinal Diseases; Male; Neoplasms; Neutropenia; Retrospective Studies | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Recombinant Proteins | 2006 |
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Neutropenia; Recombinant Proteins | 2006 |
[Transhepatic arterial chemoembolization by epirubicin mixed with microspheres for hepatocellular carcinoma].
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antibiotics, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Female; Fever; Follow-Up Studies; Hemolysis; Humans; Leukocyte Count; Liver Neoplasms; Male; Microspheres; Middle Aged; Serum Albumin; Survival Rate | 2007 |
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Heart; Heart Rate; Hospital Costs; Hospitalization; Humans; Middle Aged | 1995 |
Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Edema; Epirubicin; Exanthema; Female; Fever; Humans; Hypotension; Hypoxia; Middle Aged; Prognosis | 1999 |
Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Epirubicin; Fever; Humans; Lymphoma; Middle Aged; Nausea; Stomatitis; Vomiting | 1987 |